Document is current

Article History

Received: 6 June 2022

Accepted: 16 September 2022

First Online: 1 October 2022

Declarations

:

: All animal studies were approved by the UCLA Animal Research Committee (# 2005–090) and carried out in compliance with the ARRIVE guidelines for reporting of research involving animals. All patients were referred for ¹⁷⁷Lu-PSMA therapy under compassionate use in compliance with the German Medicinal Products Act, AMG §13 (2b). All three patients gave written informed consent to undergo ⁶⁸ Ga-PSMA PET/CT scans and potential ¹⁷⁷Lu-PSMA-TO-1 therapy following national regulations, the updated Declaration of Helsinki, and Good Clinical Practice.

: Not applicable.

: The authors have declared that no competing interests relevant to this article exist. KL reports paid consulting activities for Sofie Biosciences/iTheranostics, and funding from AMGEN outside of the submitted work. JC is a cofounder of and holds equity in Sofie Biosciences and Trethera Therapeutics. JCa reports prior consulting activities for Advanced Accelerator Applications, Blue Earth Diagnostics, Curium Pharma, GE Healthcare, EXINI, IBA RadioPharma, Janssen Pharmaceuticals, Lantheus, POINT Biopharma, Progenics, Radiomedix, and Telix Pharmaceuticals.